Please assess the completion status of the following clinical trial:

Trial Title: Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Initial from phone interview:~* Currently smoking 10-45 cigarettes per day for the past year;~* Between the ages of 21 and 70 years;~* In apparently good physical health with no unstable medical conditions including seizures or cancer;~* In stable and good mental health, i.e., currently do not experience unstable or untreated psychiatric diagnosis, including substance abuse, as determined by the DSM-IV criteria, during the past six months;~* Not using any other tobacco or nicotine-containing products;~* Not on methadone maintenance or stimulants such as ephedra; not a regular user of street drugs and if uses occasionally, willing to abstain during the study; not taking any drugs known to be P4501A6 substrates such as phenobarbital, rifampicin, dexamethasone, ketoconazole, methoxsalen, pilocarpine, or tranylcypromine due to their role in NNK metabolism;~* Does not average more than 21 alcoholic drinks per week;~* Willing to perform study activities such as having blood sample drawn, urine collection, multiple clinic visits;~* For female subjects of child bearing potential, not known to be pregnant or nursing, or planning to become pregnant within next 12 months.~For enrollment in the Short-Term Trial:~* Subjects who are generally healthy with liver enzyme and blood count values within the ranges shown below based on blood samples drawn at the second screening visit. Specifically:~  * White blood cells ≥ 3,000/mL~ * Total bilirubin ≤ 1.5 x upper limits of normal (ULN)~ * AST (SGOT)/ALT (SGPT) ≤ 2.5 x ULN~ * BUN and serum creatinine ≤ 1.5 x ULN~For enrollment in the Long-Term Trial:~* Participated in the short-term trial and invited to participate in the long-term trial;~* Possess the GSTM1 null-null genotype;~* Smoke 20 or more cigarettes/day with a cumulative smoking history of 20 or more pack-years (one pack-year equals to smoking a pack of cigarettes a day for one year);~* Normal liver enzymes based on blood sample drawn during 1 month wash-out;~* Determined to be a good candidate for the bronchoscopy procedure by a primary care physician.~Exclusion Criteria:~* Subjects with uncontrolled hypertension, uncontrolled diabetes mellitus, unstable coronary artery disease, history of cancer other than non-melanoma skin cancer, and pregnant or lactating women will not be eligible.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PEITC - Placebo (short-term trial) (Type: EXPERIMENTAL): Participants are asked to smoke only deuterated NNK cigarettes (provided by the study) and record the exact number of cigarettes smoked and alcoholic drinks consumed each day for 1 month. Participants receive oral phenethyl isothiocyanate (PEITC) four times daily for 5 days in week 2 and oral placebo four times daily for 5 days in week 4. Participants keep a diary of all food and beverages consumed on the days that PEITC or placebo are taken.
- Placebo - PEITC (short-term trial) (Type: EXPERIMENTAL): Participants receive oral placebo four times daily for 5 days in week 2 and oral PEITC four times daily for 5 days in week 4. Participants are also asked to smoke only deuterated NNK cigarettes, record the number of cigarettes smoked and alcoholic drinks consumed each day, and keep a food and beverage diary as in arm I.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete